Article thumbnail

Update on Allergy Immunotherapy

By William Davidson, Sean Lucas and Larry Borish


This article summarizes and provides commentary regarding guidelines on the administration of immunotherapy (IT) for allergic airway disease. Recent investigations have provided important insights into the immunologic mechanism of IT and the prominent role of interleukin-10-producing regulatory T lymphocytes. The most important aspect of successful IT is the administration of an appropriate dose of an extract containing a sufficient concentration of the relevant allergen. This is largely possible now only with standardized extracts. When the major allergen content of successful IT extracts was quantified, efficacy was demonstrated across a surprisingly narrow concentration range (approximately 5-24 μg per injection), irrespective of the extract. This presumably reflects the concentration of an antigen that drives an immune response toward tolerance. It may be predicted that as major allergen content is quantified in currently nonstandardized extracts, effective IT will also be achieved by administering a dose in this range, in contrast to current practices involving fairly arbitrary dosing decisions. With the availability of nonsedating antihistamines, intranasal corticosteroids, and the leukotriene modifiers, inadequate pharmacologic response or intolerable side effects are less commonly the major indications for starting IT for allergic rhinitis (AR). However, with the recognition that a relatively short course (3-5 years) of IT can provide long-term immunomodulation and clinical benefit, a desire to avoid long-term pharmacotherapy and the associated high costs may be the primary indication for IT in AR cases. While evidence overwhelmingly supports the beneficial influences of IT in asthma cases, the positioning of IT for this disorder is not established. The observed prevention of asthma in children who have AR is intriguing, but further studies are required to assess the extent to which the prevalence and severity of chronic asthma will be reduced when these children reach adulthood. Similarly, safety issues overwhelmingly suggest that uncontrolled asthma is the greatest risk factor for mortality associated with IT and that IT therefore may be contraindicated for most patients who have inadequate pharmacologic responses or are unable to tolerate useful pharmacologic agents. Paradoxically, these are the patients for whom a response to IT may be most desirable

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. A controlled trial of immunotherapy for asthma in allergic children.
  2. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever.
  3. (1997). A threeyear prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma.
  4. Allergen-specific immunotherapy in allergic rhinitis.
  5. Allergenderived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects.
  6. ARIA”: global guidelines and new forms of allergen immunotherapy.
  7. (1999). Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187–94.
  8. (1995). Canadian Society of Allergy and Clinical Immunology. Guidelines for the use of allergen immunotherapy.
  9. Conjugation of immunostimulatory DNAto the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity.
  10. (1992). Crossreacting IgE antibodies to Pityrosporum ovale and Candida albicans in atopic children. Clin Exp Allergy
  11. (1996). Effect of dilution, temperature, and preservatives on the long-term stability of standardized inhalant allergen extracts. Ann Allergy Asthma Immunol
  12. (1981). Effect of preservatives and conditions of storage on the potency of allergy extracts.
  13. (2000). Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebocontrolled studies. Clin Ther
  14. (2000). Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther
  15. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy.
  16. Immunotherapy for asthma: unfavorable studies.
  17. Immunotherapy for inhalant allergens. In: Adkinson
  18. (1999). Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy.
  19. (1996). Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy
  20. (1997). Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.
  21. Incorrect allergy injections: allergists' experiences and recommendations for prevention.
  22. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy.
  23. (1995). Is allergen immunotherapy effective in asthma? A metaanalysis of randomized controlled trials.
  24. (2000). Is specific immunotherapy safe and effective in children? Eur Rev Med Pharmacol Sci
  25. Long-term clinical efficacy of grass-pollen immunotherapy.
  26. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen.
  27. (2001). Mechanisms of T cell peptide epitope-dependent late asthmatic reactions. Int Arch Allergy Immunol
  28. (2000). Peptidemediated immune responses in specific immunotherapy. Int Arch Allergy Immunol
  29. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study).
  30. (1998). Role of interleukin 10 in specific immunotherapy.
  31. (1998). Serologic study of the working mechanisms of immunotherapy for children with perennial allergic rhinitis. Arch Otolaryngol Head Neck Surg
  32. Stability of Lolium perenne extract.
  33. (1996). Studies of allergen extract stability: the effects of dilution and mixing.
  34. (1987). Studies on Alternaria allergens. VI. Stability of the allergen components of Alternaria tenuis extracts under a variety of storage conditions. Int Arch Allergy Appl Immunol
  35. (1998). Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.
  36. (1993). Survey of fatalities from skin testing and immunotherapy 1985-1989.
  37. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001;87(1 Suppl 1):47–55.
  38. Task Force on Practice Parameters. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2003;90(1 Suppl 1):1–40.
  39. (1979). The effect of preservatives and dilution on the deterioration of Russian thistle (Salsola pestifer), a pollen extract.
  40. (1998). The epitope stability of group 1 and group 2 allergens in mite extracts. Ann Allergy Asthma Immunol
  41. The stability of house dust mite allergens in glycerinated extracts.
  42. The use of standardized extracts in allergen immunotherapy.
  43. The value of hyposensitization therapy for bronchial asthma in children—a 14-year study. Pediatrics 1968;42:793–802.
  44. (2001). Three years of specific immunotherapy with housedust-mite extracts in patients with rhinitis and asthma: significant improvement of allergenspecific parameters and of nonspecific bronchial hyperreactivity. Allergy
  45. (1990). Twelve-year survey of fatal reactions to allergen injections and skin testing:
  46. (1998). WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy